Brokerages Set Alpha Tau Medical Ltd. (NASDAQ:DRTS) Price Target at $12.60

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has received an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.60.

Several equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Friday, July 17th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. LADENBURG THALM/SH SH increased their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Barclays increased their target price on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Finally, Piper Sandler lifted their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th.

Insider Buying and Selling at Alpha Tau Medical

In other news, CFO Raphi Levy sold 32,500 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the sale, the chief financial officer owned 147,680 shares of the company’s stock, valued at $1,599,374.40. This represents a 18.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 112,270 shares of company stock valued at $1,270,923 in the last ninety days. 39.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alpha Tau Medical

Several hedge funds have recently bought and sold shares of the company. Trifecta Capital Advisors LLC acquired a new stake in shares of Alpha Tau Medical in the fourth quarter valued at approximately $48,000. Envestnet Asset Management Inc. bought a new stake in Alpha Tau Medical in the 3rd quarter valued at $62,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Everhart Financial Group Inc. bought a new position in Alpha Tau Medical during the second quarter worth $126,000. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Trading Up 1.2%

Shares of NASDAQ DRTS opened at $13.14 on Friday. Alpha Tau Medical has a 1-year low of $3.00 and a 1-year high of $14.11. The company has a 50-day moving average of $11.50 and a two-hundred day moving average of $9.11. The company has a market cap of $1.19 billion, a PE ratio of -19.61 and a beta of 1.17. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, equities analysts expect that Alpha Tau Medical will post -0.67 earnings per share for the current fiscal year.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.